OKYO Pharma Limited (EMMLF) Research

OKYO Pharma Limited is an early-stage biopharmaceutical company focused on developing therapies for individuals experiencing inflammatory eye conditions and ocular pain. A key asset in their pipeline is OK-101, specifically aimed at treating dry eye disease. Additionally, the company is advancing OK-201, which is a preclinical lipidated-peptide analogue sourced from bovine adrenal medulla, intended for the management of neuropathic ocular pain. Founded in 2007, OKYO Pharma Limited is headquartered in London, United Kingdom.

Market snapshot

Symbol
EMMLF
Price
$0.01
Day change
0.00%
Market cap
$22.7M
52-week range
0.0137-0.890499
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • American Hemp Ventures, Inc. (AMHV)
  • IBEX Technologies Inc. (IBXNF)
  • Kadimastem Ltd (KMSTF)
  • Organicell Regenerative Medicine, Inc. (OCEL)
  • OptiBiotix Health Plc (OPBXF)
  • PharmChem, Inc. (PCHM)
  • Rapid Dose Therapeutics Corp. (RDTCF)
  • Renalytix Plc (RTNXF)

Open OKYO Pharma Limited (EMMLF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.